Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKANNASDAQ:GNPXNASDAQ:INDPNASDAQ:OMGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKANAkanda$1.16-4.9%$1.29$0.93▼$47.52$1.66M1.51337,555 shs8,936 shsGNPXGenprex$0.22-20.9%$0.30$0.21▼$4.09$5.39M-0.43.79 million shs3.63 million shsINDPIndaptus Therapeutics$0.42-3.7%$0.55$0.36▼$3.10$6.79M1.49144,629 shs55,706 shsOMGAOmega Therapeutics$0.13-21.8%$0.12$0.10▼$2.63$6.92M1.653.02 million shs4.81 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKANAkanda-0.33%+1.24%+10.91%-29.07%-83.53%GNPXGenprex+2.14%-3.46%+5.78%-40.75%-88.21%INDPIndaptus Therapeutics+5.69%+2.33%-8.33%-41.22%-79.25%OMGAOmega Therapeutics0.00%0.00%0.00%-51.92%-94.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKANAkandaN/AN/AN/AN/AN/AN/AN/AN/AGNPXGenprex4.1467 of 5 stars3.52.00.04.73.50.01.3INDPIndaptus Therapeutics3.4799 of 5 stars3.55.00.00.02.81.71.3OMGAOmega Therapeutics1.8693 of 5 stars3.40.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKANAkanda 0.00N/AN/AN/AGNPXGenprex 3.00Buy$10.004,384.30% UpsideINDPIndaptus Therapeutics 3.00Buy$8.501,906.61% UpsideOMGAOmega Therapeutics 2.80Moderate Buy$9.207,260.00% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKANAkanda$836.66K1.98N/AN/A($76.10) per share-0.02GNPXGenprexN/AN/AN/AN/A$4.99 per shareN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/AOMGAOmega Therapeutics$8.10M0.85N/AN/A$1.05 per share0.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKANAkanda-$32.28MN/A0.00∞N/AN/AN/AN/AN/AGNPXGenprex-$30.86MN/A0.00N/AN/AN/A-409.48%-269.17%5/21/2025 (Estimated)INDPIndaptus Therapeutics-$15.42M-$1.62N/AN/AN/AN/A-177.27%-141.06%5/14/2025 (Estimated)OMGAOmega Therapeutics-$97.43M-$1.33N/AN/AN/A-902.93%-213.13%-41.24%6/20/2025 (Estimated)Latest AKAN, OMGA, INDP, and GNPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AGNPXGenprex-$0.82N/AN/AN/AN/AN/A5/14/2025Q1 2025INDPIndaptus Therapeutics-$0.41-$0.32+$0.09-$0.32N/AN/A5/12/2025Q1 2025GNPXGenprex-$0.82-$0.26+$0.56-$0.26N/AN/A3/13/2025Q4 2024INDPIndaptus Therapeutics-$0.41-$0.38+$0.03-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKANAkandaN/AN/AN/AN/AN/AGNPXGenprexN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/AOMGAOmega TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKANAkandaN/A1.41N/AGNPXGenprexN/A0.860.86INDPIndaptus TherapeuticsN/A3.423.42OMGAOmega Therapeutics1.001.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKANAkanda1.00%GNPXGenprex14.05%INDPIndaptus Therapeutics7.06%OMGAOmega Therapeutics97.47%Insider OwnershipCompanyInsider OwnershipAKANAkanda20.39%GNPXGenprex8.47%INDPIndaptus Therapeutics29.50%OMGAOmega Therapeutics8.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKANAkanda1101.43 million1.14 millionNot OptionableGNPXGenprex2024.15 million7.79 millionNo DataINDPIndaptus Therapeutics616.03 million9.96 millionNot OptionableOMGAOmega Therapeutics12055.37 million50.66 millionOptionableAKAN, OMGA, INDP, and GNPX HeadlinesRecent News About These CompaniesOmega Therapeutics Inc (OMGAQ)March 5, 2025 | investing.comHuge distressed drugmaker seeks sale in Chapter 11 bankruptcyFebruary 27, 2025 | msn.comIntrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & ImmunologyFebruary 19, 2025 | markets.businessinsider.comOmega Therapeutics secures $9.8M in DIP financingFebruary 14, 2025 | msn.comOmega Therapeutics Hits Chapter 11February 10, 2025 | usaherald.comFlagship’s Omega Thera to file for bankruptcyFebruary 5, 2025 | thepharmaletter.comFlagship-backed Omega signals it’s headed toward bankruptcyFebruary 5, 2025 | biopharmadive.comThe OMGA Conundrum: Why Omega Therapeutics Inc’s Stock Is Making Headlines AgainFebruary 5, 2025 | bovnews.comNovo Partner Omega Waves Bankruptcy Flag from Sinking ShipFebruary 4, 2025 | biospace.comFlagship spinout Omega is days away from bankruptcy, it says in filingFebruary 4, 2025 | endpts.comWhat’s Behind the 11.36% Gain in Omega Therapeutics Inc (OMGA) Stock? Find Out Now!January 30, 2025 | bovnews.comOmega Therapeutics announces board reshuffle and new directorJanuary 29, 2025 | msn.comFlagship Pioneering partners with Cambridge, UK institutionsJanuary 25, 2025 | thepharmaletter.comOmega Therapeutics stock hits 52-week low at $0.52January 21, 2025 | msn.comOmega Therapeutics Appoints New Director Ravi MehrotraDecember 6, 2024 | tipranks.comOmega Pacific Reports Its Final Drill Hole Yielding Multiple Zones of Mineralization at Its Williams PropertyDecember 4, 2024 | accesswire.comOmega Pacific Announces 2024 Work Program Results From Its Lekcin PropertyNovember 19, 2024 | accesswire.comOmega Therapeutics Reports Third Quarter 2024 ResultsNovember 19, 2024 | markets.businessinsider.comOmega Therapeutics price target lowered to $4 from $9 at Piper SandlerNovember 16, 2024 | markets.businessinsider.comPiper Sandler Remains a Buy on Omega Therapeutics (OMGA)November 16, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKAN, OMGA, INDP, and GNPX Company DescriptionsAkanda NASDAQ:AKAN$1.16 -0.06 (-4.92%) As of 03:59 PM EasternAkanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.Genprex NASDAQ:GNPX$0.22 -0.06 (-20.89%) As of 04:00 PM EasternGenprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Indaptus Therapeutics NASDAQ:INDP$0.42 -0.02 (-3.73%) As of 03:59 PM EasternIndaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Omega Therapeutics NASDAQ:OMGA$0.12 -0.03 (-21.83%) Closing price 02/24/2025Extended Trading$0.12 0.00 (0.00%) As of 02/24/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
